TAVLESSE

This brand name is authorized in Austria, Estonia, Spain, Finland, Ireland, Lithuania, Poland, United Kingdom

Active ingredients

The drug TAVLESSE contains one active pharmaceutical ingredient (API):

1 Fostamatinib disodium hexahydrate UNII 86EEZ49YVB - FOSTAMATINIB DISODIUM

Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK), through its major metabolite R406. R406 reduces antibody-mediated destruction of platelets. Fostamatinib is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients. Read about Fostamatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TAVLESSE Film-coated tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BX09		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1809480, 1809491, 1809503, 1809514
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1191405001, 1191405002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 132187, 192372
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 387056, 387058
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1089186, 1089187
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100429958, 100429964